Peptech patent approved
Tuesday, 15 July, 2003
Peptech's application for a patent on antibodies or antibody fragments that bind to a specific tumour necrosis factor (TNF) has been given the green light by US patent authorities.
Managing director Mr Stephen Kwik noted that the new patent enhanced the company's already considerable anti-TNF patent portfolio, and offered the potential for further coverage under the current description.
"As the peptide represents a portion of the TNF molecule, anti-TNF antibodies that bind the peptide could fall under the scope of the patent," Kwik said.
Peptech has already licensed its technology in the fields of antibody therapeutics for inflammatory diseases such as rheumatoid arthritis, psoriasis and Crohn's disease.
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
MV Hondius passengers return to Australia under strict infection control measures
The Australian CDC has provided an update on hantavirus risk to Australians and infection...
